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Abstract
Background: The two typhoid vaccines, the parenteral Vi capsular polysaccharide and the oral live whole-cell Salmonella
Typhi Ty21a vaccine, provide similar levels of protection in field trials. Sharing no antigens, they are thought to confer
protection by different mechanisms. This is the first head-to-head study to compare the humoral immune responses to
these two vaccines.
Methods: 50 age- and gender-matched volunteers were immunized, 25 with the Vi and 25 with the Ty21a vaccine.
Circulating plasmablasts reactive with whole-cell Salmonella Typhi or one of the typhoidal antigenic structures, Vi, O-9,12,
and H-d antigens, were identified as antibody-secreting cells (ASC) with ELISPOT. Homing receptor (HR) expressions were
determined. These results were compared with ASC in four patients with typhoid fever. Antibodies to S. Typhi
lipopolysaccharides were assessed in cultures of ALS (antibodies in lymphocyte supernatants) and in serum with ELISA.
Results: In 49 out of 50 vaccinees, no typhoid-specific plasmablasts were seen before vaccination. On day 7, response to Vi
antigen was mounted in 24/25 volunteers in the Vi, and none in the Ty21a group; response to S. Typhi and O-9,12 was
mounted in 49/50 vaccinees; and to H-d in 3/50. The numbers of typhoid-specific plasmablasts (total of ASC to Vi, O-9,12
and H-d antigens) proved equal in the vaccination groups. The HR expressions indicated a mainly systemic homing in the Vi
and intestinal in the Ty21a group, the latter resembling that in natural infection. Plasmablasts proved more sensitive than
serum and ALS in assessing the immune response.
Conclusions: The typhoid-specific humoral responses to Vi and Ty21a vaccines are similar in magnitude, but differ in
expected localization and antigen-specificity. The unforeseen O antigen-specific response in the Vi group is probably due to
lipopolysaccharide contaminating the vaccine preparation. Only the response to Ty21a vaccine was found to imitate that in
natural infection.
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Introduction
Typhoid fever continues to comprise a significant health
problem in developing countries, posing a risk for travellers as
well [1,2]. Two vaccines are available for clinical use: the
parenteral Vi capsular polysaccharide vaccine, and the oral live
Salmonella Typhi Ty21a vaccine [1–4]. Both have proved
immunogenic, providing similar levels of protection against
typhoid fever in clinical trials [2–4], yet there are no
head-to-head studies comparing their immunogenicity and pro-
tective efficacy. As the two vaccines do not share antigens, the
immune mechanisms underlying their protective efficacy have
been considered entirely different [2].
The Vi antigen is thought to be one of the major virulence
factors of S. Typhi [5]. Vaccines based on Vi capsular
polysaccharide have been purified from strain S. Typhi Ty2.
These parenterally administered vaccines have conferred a
protection of 55–68% [4,6–8] while causing only a low rate of
adverse effects [9]. The vaccine has been considered to contain
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solely Vi polysaccharide. Accordingly, the protection has been
thought to be mediated on serum Vi-specific antibodies [2].
Oral S. Typhi Ty21a vaccine is a live, attenuated whole cell
preparation containing all other typhoidal structures but the Vi
polysaccharide. It has conferred 51–69% protection in field trials
[4,10–12]. The immune mechanisms contributing to protection
have been considered to include both humoral and cell-mediated
immune mechanisms [13–19], the route of the antigen encounter
and the mode of action imitating that of a natural infection.
An immune response to any vaccine begins with the appearance
of antigen-specific plasmablasts in the circulation in humans
[13,16,20–23]. These represent the effector cells of humoral
immunity being distributed to their final effector sites. While the
blood flow takes these plasmablasts with equal efficacy everywhere
in the body, they can cross the endothelial lining and enter the
various tissues only if they carry the types of homing receptors
(HR) and chemokine receptors required for homing to that
particular tissue [24]. The HR and chemokine receptors
expressions can be utilized in the evaluation of the localization
of an immune response [22,25–29]. The a4b7 -integrin has been
recognized as the HR guiding the cells to home to the intestine
[30], and L-selectin as the HR mainly mediating more systemic
homing [31]. An intestinal homing profile after Ty21a vaccination
has been recorded in several studies [22,25–28]. We are not aware
of any studies characterizing circulating plasmablasts or their
homing profile after Vi vaccination.
We conducted a head-to-head study with age- and gender-
matched volunteers to compare the magnitude, antigen-specificity
and localization of humoral immune responses to the two vaccines.
These preparations are not considered to share any structures in
common, thus our initial hypothesis was that the plasmablast
responses would be targeted against different antigens, yet we
wanted to compare the number of plasmablasts and the
localization of the response as evaluated by the expression of
homing receptors on the plasmablasts. In addition to getting
answers to our initial questions, we also found that the antigen-
specificities in the plasmablast responses did not differ as much as
had been thought.
Materials and Methods
Ethics Statement
The study protocol was approved by the ethics committee of the
Helsinki University Central Hospital and the Finnish Medicines
Agency, and registered in the International Standard Randomised
Controlled Trial Number Register (ISRCTN68125331). Written
informed consent was obtained from all study subjects.
Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Volunteers vaccinated with Vi and Ty21a vaccines were
examined for circulating plasmablasts reactive with strains
expressing various typhoidal antigens. The data were compared
to those for patients with typhoid fever whose data have been
published in our previous studies [32,33]. Plasmablasts were
identified by enzyme-linked immunospot assay (ELISPOT) as
antigen-specific antibody-secreting cells (ASC). The homing
potentials of S. Typhi- specific plasmablasts were characterized
by combining immunomagnetic cell sorting with the ELISPOT.
Levels of specific antibodies were determined by ELISA in the
serum and ALS (antibodies in lymphocyte supernatants) samples
of the vaccinees (Figure 1). The study was conducted in Helsinki
University Central Hospital and at the Haartman Institute,
University of Helsinki between December 2009 and October
2010.
Notably, this report presents only a part of the results of the
study protocol provided as a supplementary material. Two recent
reports included parts of the data on the same project [32,33].
Volunteers, Vaccinations and Samples
The volunteers enrolled were fifty age- and gender-matched
healthy Finnish-born volunteers (both groups comprised 17
females, 8 males, all aged 22–62, mean 32 years) (Table 1) with
no history of enteric fever or typhoid vaccination, the numbers of
volunteers were evaluated in pre-study power calculations based
on responses in pilot experiments. Twenty-five of them received
the parenteral Vi capsular polysaccharide vaccine (TypherixH,
GlaxoSmithKline Biologicals s.a., Rixensart, Belgium, lots
ATYPB084BC and ATYPB096AF), and 25 were administered
the oral vaccine containing $26109 live Salmonella Typhi Ty21a
bacteria (VivotifH Crucell NV, Leiden, The Netherlands, lot
3001777) The amount of contaminating endotoxin in the
Figure 1. Flow diagram of the study: study groups and timing
of samples.
doi:10.1371/journal.pone.0060583.g001
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Typherix vaccine preparation was 27.00 EU per dose for lot
ATYPB084BC and 13.30 EU per dose for lot ATYPB096AF (data
provided by the manufacturer). The vaccine type given to the first
volunteer of each age was determined by raffle and the second,
age- and gender-matched subject, was given the other vaccine
type. Notably, the results of the assays on the coded ELISPOT
plates were read by a blinded person with no knowledge about the
types of vaccine given in the various cases, or which plates
represented age- and gender-matched pairs. The Vi vaccine was
injected with a 25 mm needle as one 0.5 ml intramuscular dose in
the left arm on day 0. The Ty21a vaccine was given one capsule
on each of days 0, 2, and 4, as recommended by the manufacturer.
The data of S. Typhi and H-d-specific ASC in volunteers
immunized with the Ty21a has been included as a part of a
larger recently published set of data [32,33], where no age- and
gender-matched controls were included, while the data on the O-
9,12-specific responses have not been presented until now. Both
vaccines proved well-tolerated. The adverse effects are described
in Table 1. There were no drop-outs in the study.
The typhoid fever patients have been described earlier [32,33]:
two were Finnish-born travellers returning from Central-America
and India, the third was a Sri Lankan applying for asylum, and the
fourth a Nepalese immigrant with an infection relapse one month
after the first episode. S. Typhi strains of the patients were all Vi
positive. The data on homing profiles in the patients with primary
infection have been reported before, pooled with data from a
paratyphoid fever patient [32,33]; data on the homing profiles of
the patient with relapse have not been presented until now.
In our previous studies on mucosal [13,19–21] and parenteral
[19] immunization, ASC have been found to appear transiently in
the circulation on day 2–3, peaking on day 7 [13,19,20].
Accordingly, blood samples were drawn before vaccination and
7 days after it (ELISPOT and ALS), or 7–10 days after the onset of
infection symptoms (ELISPOT). Serum samples were collected
before and 28 days after vaccination.
Antigens for ELISPOT
Vi antigen and four whole-cell bacterial strains were used as
antigens in the ELISPOT assay (Table 2). As Vi antigen we
applied the actual Vi vaccine preparation (TypherixH) at a
concentration of 10 mg/ml PBS for coating. The bacterial strains
were from the collection of the National Institute for Health and
Welfare, Helsinki, Finland. They were chosen to cover selected
parts of S. Typhi: Salmonella Typhi (all antigens), Salmonella strain
SL2404 (O-9 and 12 antigens), Salmonella Egusi (H-d antigen) and
Yersinia enterocolitica (no antigens in common; negative control). The
expressions of the various typhoidal antigens were confirmed in
the reference laboratory according to standard methods. The
preparation of these strains for use as antigens has been described
earlier [32].
Isolation of Peripheral Blood Mononuclear Cells (PBMC)
PBMC were separated using Ficoll-Paque centrifugation as
described earlier [13].
Separation of the Receptor-negative and -positive Cell
Populations
The expressions of HR on S. Typhi-specific ASC were explored
in seven vaccinees in the Vi group and compared to those of nine
vaccinees in the Ty21a group reported earlier [32]. Separation of
the cells into HR-positive and -negative populations has been
described earlier [23,25–27,29]. Briefly, aliquots of cell suspen-
sions were incubated with monoclonal antibodies against a4b7
(ACT-1, Millennium Pharmaceuticals, Cambridge, MA), L-
selectin (Leu 8, Becton Dickinson, Erenbodegem-Aalst, Belgium),
or CLA (HECA-452, a gift from Dr. Sirpa Jalkanen, Finland).
Next, the cells were incubated with DynalHM-450 magnetic beads
coated with sheep anti-mouse IgG (Dynabeads, Dynal Biotech,
Oslo), followed by magnetic separation. Separated cells were
immediately studied with the ELISPOT assay.
ELISPOT Assay of Specific ASC
The isolated PBMC and, for HR analyses, the receptor-positive
and -negative cell populations were assayed for antigen-specific
ASC using ELISPOT, as described earlier [13]. Briefly, the cells
were incubated for two hours in 96-well microtiter plates
(Maxisorp, Nunc, Roskilde, Denmark) coated in advance with
antigens described above. The cells were incubated in the wells for
2 hours (26106 PBMC/mL, 50 mL/well, total 2.46106 PBMC per
antigen). The antibodies secreted were detected with alkaline
phosphatase-conjugated anti-human IgA (Sigma-Aldrich), IgG
(Sigma-Aldrich) and IgM (SouthernBiotech, Birmingham, En-
gland). The substrate (5-bromo-4-chloro-3-indolyl phosphate p-
toluidine salt; Sigma-Aldrich) was added in melted agarose. The
spots were enumerated with an AID Elispot reader, and each spot
was interpreted as a print of one ASC. The specificity, linearity,
stability, and intermediate precision of the ELISPOT assay have
been validated. A responder was defined as a person with at least 3
IgA– +IgG+IgM–ASC/106 PBMC, and marked as LOD (limit of
detection) of the response in the Figures. This limit has been
determined over the assay validation process.
ALS Cultures
PBMC were cultured in RPMI 1640 medium supplemented
with 3 mg/mL L-glutamine (2 mM), penicillin (100 mg/mL) and
streptomycin (100 mg/mL), and 10% fetal calf serum in flat-
bottomed 96-well plates at 37uC in 5% CO2 (2610
6 PBMC/
200 mL/well). Supernatants were collected after three days, and
stored at 270uC until assayed.
ELISA
Antibodies (IgA, IgG and IgM) in serum and ALS samples were
measured with ELISA as described earlier [33]: microtiter plates
(Polysorp, Nunc) were coated with a preparation of LPS of S.
Typhi (Sigma-Aldrich; 10 mg/mL 30% methanol-PBS), and
Table 1. Baseline characteristics and adverse effects reported
in 50 volunteers immunized with typhoid fever vaccines.
Vi vaccine Ty21a vaccine
n 25 25
mean age (range) 32 (22–62) 32 (22–62)
female 17 17
male 8 8
adverse effects
fever 1 –
pain at the injection site 2 –
constipation 1 –
loose stools 1 –
stomach ache – 2
tiredness – 1
doi:10.1371/journal.pone.0060583.t001
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blocked with 5% milk-PBS solution. Next, the samples diluted in
blocking solution were incubated in the wells overnight. The
horseradish peroxidase (HRP)-conjugated rabbit anti-human IgA,
IgG and IgM antibodies (all from Dako) was used as a secondary
antibody, and the colour was developed with TMB peroxidase
substrate (3,3’,5,5’- tetramethylbenzidine and H2O2 in citric acid
buffer; KPL, Gaithersburg, USA), and stopped with 0.5 M sulfuric
acid. A response was defined as at least two-fold increase in the
titre from the prevaccination level in the specific antibody titres.
Statistics
Statistical analyses were carried out with JMP software, version
9.0.0 (SAS Institute Inc, Cary, NC, USA). The distribution of the
ASC and HR expressions was tested with Shapiro-Wilk’s test.
Since not all distributions proved normal even after log
transformations, Bonferroni-corrected Wilcoxon signed rank test
was used for comparisons between the responses to various
antigens, and Wilcoxon signed rank test between two groups. The
results are given as the means, medians, and 95% confidence
intervals (CI) for the number of ASC, and as means 695%CI for
the HR expressions.
The proportions of the receptor-positive ASC were calculated as
follows: percentage of receptor-positive ASC= (1006 the number
of ASC in receptor positive cell population)/(the total of of ASC in
receptor-positive and -negative cell populations).
Results
ASC Response in the Vi Group
Before vaccination, 24 out of the 25 vaccinees had no ASC
specific to any of the antigens in their circulation (Figure 2a). One
volunteer had 355 ASC/106 PBMC to Salmonella Typhi, 40 to O-
9,12, 40 to H-d and 308 to Yersinia enterocolitica, but none to Vi
antigen. As he had just one week earlier recovered from of a febrile
respiratory tract infection, the ASC were interpreted as a sign of
polyclonal stimulation.
Seven days after vaccination, 24 out of 25 volunteers showed a
response to the Vi polysaccharide and to S. Typhi, 22/25 to O-
9,12, and 2/25 to H-d (Figure 2 and 3). The highest numbers were
found with the Vi antigen and S. Typhi (Figure 2a, 3, Table 2), yet
a substantial response was also seen to O-9,12. The responses were
mainly dominated by IgA and IgM (Figure 4).
ASC Response in the Ty21a Group
Before vaccination, none of the vaccinees had plasmablasts
specific to any of the antigens. (Figure 2b). Seven days after
vaccination, circulating S. Typhi and O-9,12 -specific ASC were
detected in all vaccinees, while no response was seen to Vi antigen
or H-d (Figure 2b, 3, Table 3). Here, too, the responses were
mostly dominated by IgA and IgM (Figure 4).
Comparison of the ASC Responses between Vi and Ty21a
Groups
Statistical comparisons between the responses in the two vaccine
groups are shown in Figure 3. The response to the Vi antigen was
significantly higher in the Vi group, and to O-9,12 in the Ty21a
group. The total response to typhoid antigens was assessed by two
approaches: as the response to whole cell S. Typhi, and as a total
of responses to individual typhoid antigens (Vi+O-9,12+ H-d). No
significant differences were seen between the groups by the latter
approach.
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Expression of a4b7, L-selectin and CLA on Specific ASC
The numbers of PBMC obtained only allowed a HR analysis on
plasmablasts specific to one antigen. The whole-cell S. Typhi was
chosen for this. In the Vi group, a systemic homing profile was
seen: 84% of all S. Typhi-specific ASC expressed the peripheral
lymph node HR, L-selectin, and only 56% the intestinal HR,
a4b7-integrin, and 4% the cutaneous HR, CLA. In the Ty21a
group the HR profile was mucosal, as evidenced by the very high
expression of a4b7 (95%) and lower expression of L-selectin (27%)
(Figure 5); these data on HR expressions on S. Typhi-specific
plasmablasts in Ty21a-vaccinated volunteers were retrieved from
our previous report [32] to allow comparison between the two
vaccine groups. The comparison to the HR-profile in natural
typhoid fever (a4b7 91%, L-selectin 40%, CLA 11%) obtained
from the data base of our previous study [32] showed that only the
response in the Ty21a group imitated that in a natural infection.
The case of relapsed typhoid fever had a unique profile with a high
expression of all HR (a4b7 95%, L-selectin 66%, CLA 65%).
Antibodies in ALS and Serum Samples
The number of vaccinees with a twofold or higher rise in
antibody titres in serum and ALS samples was smaller than of
those responding in the ELISPOT assay (Table 4).
Discussion
The present study is the first head-to-head study comparing
immune responses to Vi and Ty21a vaccines, the two typhoid
vaccines currently available. We found similar numbers of
typhoid-specific plasmablasts in the circulation of the vaccinees
in both groups, yet the homing profiles were found to be different.
As an unforeseen finding, the antigen-specificity of these responses
proved less different than had been thought.
Until now, no studies have explored circulating Vi-specific
plasmablasts in volunteers receiving typhoid vaccines. A clear Vi-
specific response was mounted in the Vi group, while none in the
Ty21a group responded to this antigen, in alignment with the lack
of Vi antigen in the Ty21a strain. In the Ty21a group, the highest
response was mounted to O-9,12 antigen. No response to O-9,12
was initially anticipated in the Vi group, yet O-antigen-specific
plasmablasts were found in almost all vaccinees. Even if
significantly lower than in the Ty21a group, the response was
clear.
The response to the typhoidal O-antigen in the Vi group calls
for an explanation. A logical reasoning derives from the fact that
the Vi polysaccharide was initially isolated from the Salmonella
Typhi Ty2 strain. Since it is not an easy task to remove the
contaminating lipopolysaccharide (LPS), traces of typhoidal LPS
Figure 2. Plasmablasts on days 0 and 7 after immunization with Vi capsular polysaccharide or Salmonella Typhi Ty21a vaccines.
Numbers of circulating plasmablasts specific to Vi, O-9,12 and H-d antigens, and to Yersinia enterocolitica representing a negative control. The
plasmablasts were identified as antibody-secreting cells (ASC) in (a) 25 volunteers vaccinated with the parenteral Vi capsular polysaccharide vaccine
and in (b) 25 age- and gender-matched volunteers receiving the oral live whole-cell Salmonella Typhi Ty21a vaccine lacking the Vi antigen. The dots
represent results of individual vaccinees, and the lines the medians of the numbers of Ig(A+G+M)-plasmablasts on day 0 and 7 after vaccination.
LOD= lower limit of detection of the response.
doi:10.1371/journal.pone.0060583.g002
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are likely to be left in the final preparation. This amount appears
small enough not to cause adverse effects typical to parenteral
whole-cell typhoid vaccines, yet high enough for the immune system
to recognize it. In fact, in early studies, serum antibodies to LPS had
been reported in Vi vaccinees, the levels correlating positively to the
LPS content of the preparation: 5% of LPS caused seroconversion
in 83% of vaccinees, and 0.2% of LPS in only 26% [9].
In the present study, no immune response to H-d antigen was
observed. In our previous study, a plasmablast response against H-d
antigen was found after parenteral whole-cell Ty21a, but not after
oral Ty21a vaccination [19], suggesting immunization route-
dependent differences in processing the antigen. In the present
study, the lack of response to H-d found in the Vi group suggests
that either the antigen has been destroyed in the vaccine purification
process, or the amount that is left of it remains too low to elicit a
measurable response.
Previous studies with Ty21a vaccines have shown that the
numbers of plasmablasts 7 days after vaccination correlate with
levels of effectiveness observed in field trials using the same
immunization regimen [10,13]. As the Vi and Ty21a vaccines
have in various field trials been reported to confer a similar degree
of protection, we were curious to know whether they elicit similar
levels of typhoid-specific plasmablasts in the circulation. The total
typhoid-specific response was estimated with two separate
Figure 3. Comparison of the typhoid-specific plasmablast response in the two vaccination groups. Comparison of the numbers of
circulating antigen-specific plasmablasts (ASC) between 25 volunteers immunized with the parenteral Vi vaccine and 25 with the oral Ty21a vaccine.
Plasmablasts were examined for specificity against the Vi, O-9,12, and H-d antigens, against Yersinia enterocolitica acting as a negative control and
against whole-cell S. Typhi. The numbers of typhoid-specific plasmablasts are also indicated as a total of cells reactive with Vi, O-9,12 and H-d
antigens. The dots represent results of individual vaccinees, and the lines the means of the numbers of Ig(A+G+M)-plasmablasts on day 7 after
vaccination. The statistical comparisons (Bonferroni-corrected Wilcoxon signed rank test) between the strains in the two vaccination groups are
indicated with asterisks (***p,0,001; **0.001,p,0.01, *p,0,05) above the bars. LOD= lower limit of detection of the response. No LOD values are
given for Vi+O-9,12+ H-d, since this does not represent a result of the assay, but a calculated total value for three different antigens.
doi:10.1371/journal.pone.0060583.g003
Table 3. Magnitude of the plasmablast responses to various antigens and results of statistical comparisons in the Ty21a group.
Antigens and magnitude of the response in
the Ty21a-vaccinated volunteers Comparison with
Antigen Mean (95%CI) Vi antigen O-9,12 H-d Neg. control S. Typhi
Vi antigen 1 (0–1)
O-9,12 337 (154–520) ***
H-d 1 (0–1) NS ***
Neg. control 0 (0–1) NS *** NS
S. Typhi 314 (147–481) *** NS *** ***
Sum of typhoid antigens
(Vi+O-9,12+ H-d)
339 (155–521) *** NS *** *** NS
The number of plasmablasts (ASC/106 PBMC) reactive with the strains (means and 95% confidence intervals), and statistical comparison (Bonferroni-corrected Wilcoxon
signed rank test) between the responses in 25 volunteers vaccinated with the Ty21a vaccine one week earlier. Significant differences are indicated with asterisks
(***p,0.001; **0.001,p,0.01; *0.01,p,0.05), NS = not significant.
doi:10.1371/journal.pone.0060583.t003
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approaches: by using whole-cell S. Typhi as antigen in the assay,
and by calculating the total of plasmablast responses to all
typhoidal antigens measured, i.e. to Vi, O-9,12, and H-d antigens.
In the Ty21a group these two approaches yielded identical results,
whereas in the Vi group the former approach appeared less
sensitive than the latter. We suggest that using whole-cell S. Typhi
as an antigen may not allow a sufficiently high concentration of the
Vi antigen in the assay or, alternatively, the Vi polysaccharide may
have been partly destroyed by formalin, when preparing the strain
for the assay. Therefore, the response to Vi antigen should be
assessed separately, as was done in the latter approach. The total of
the response to the different typhoidal antigens (Vi+O-9,12+ H-d)
Figure 4. Immunoglobulin isotype distribution. Immunoglobulin isotype distribution of antibodies secreted by plasmablasts reactive with Vi
and O-9,12 antigen (ASC/106 PBMC) in 25 volunteers immunized with the Vi capsular polysaccharide, and with O-9,12 antigen in 25 volunteers
immunized with the Salmonella Typhi Ty21a vaccine. The dots represent results of individual vaccinees, and the lines the medians of the numbers of
plasmablasts secreting specific antibodies of the IgA, IgG or IgM isotype on day 7 after vaccination.
doi:10.1371/journal.pone.0060583.g004
Figure 5. Homing potentials of Salmonella Typhi-specific plasmablasts in the two vaccination groups. The expression of a4b7, L-selectin
and CLA on Salmonella Typhi-specific plasmablasts in the peripheral blood of volunteers seven days after vaccination with the Vi or the Ty21a
vaccine. The bars indicate the arithmetic means +95%CI of percentages of HR-positive ASC among all pathogen-specific ASC (IgA+IgG+IgM). The HRs
and the numbers of volunteers from whom the data were pooled are indicated under the data bars. The data on HR expressions on S. Typhi-specific
plasmablasts in Ty21a-vaccinated volunteers has been reported earlier [32]. The statistical comparisons (Wilcoxon signed rank test) between the
strains in the two vaccination groups are indicated with asterisks (***p,0,001; **0.001,p,0.01, *p,0,05).
doi:10.1371/journal.pone.0060583.g005
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was found to be similar in the two vaccine groups, consistent with
the similar efficacy of these vaccines in field trials [2–4].
Interestingly, the magnitude of the response in a natural typhoid
infection (for three patients mean specific ASC/106 PBMC against
S. Typhi 343, O-9,12 216, H-d 3 and Yersinia enterocolitica 3) in our
previous studies [32,33] appears similar to that reported for the two
vaccine groups in the present study.
Immunity to typhoid fever is considered to consist of several
factors, including both cell-mediated and humoral immune
mechanisms [13–19]. The conception that the immune mecha-
nisms of these two vaccines are totally different would imply that
typhoid immunity can be attained in at least two entirely different
ways: through antibodies against Vi antigen (as with Vi vaccine) or
by several other mechanisms, e.g. by eliciting cell-mediated
immune responses, by specific intestinal secretory IgA, and LPS-
specific serum antibodies (Ty21a vaccine). However, an O-
antigen-specific plasmablast response also conferred by the Vi
vaccine suggests that the current conception of the protective
mechanisms of this vaccine may need to be revisited. O-antigens
are considered to contribute to the defence conferred by whole-cell
parenteral vaccines: protective efficacy has been reported by
vaccines prepared both from Vi-positive (K strain) and -negative
(L strain) S. Typhi strains [34]. Interestingly, Citrobacter 5396/38
and S. Typhi have identical Vi antigens. In early studies, Vi
polysaccharide isolated from the Citrobacter strain was found to be
less effective than the one isolated from S. Typhi [35]. The authors
wondered whether the isolation of Vi antigen had been less
successful from the Citrobacter than S. Typhi Ty2 strain. One might
also argue that only the latter preparation contained typhoidal
LPS. Similarly, it thus appears possible that the protection
conferred by the current Vi vaccines, while mainly depending
on Vi-specific mechanisms, could also include mechanisms specific
to the O-antigen part.
The homing profile of the plasmablasts reflects the expected
localization of the immune effector cells in the body. The
plasmablasts in the Vi group exhibited a systemic homing profile,
with a high frequency of L-selectin- and a lower frequency of a4b7-
and CLA-expressing cells. In the Ty21a group, by contrast, the
homing profile was intestinal [32], with all cells expressing a4b7,
and a lower proportion L-selectin and CLA. These results are
consistent with previous studies on oral [23,25–29] and parenteral
[25,27] antigen administration showing that the expression of HR
depends on the site of antigen encounter [25,27]. Both intestinal
and systemic immune defence is needed in the protection against
typhoid fever. The intestinal targeting appears particularly
beneficial from the perspective that the pathogen uses this site as
a portal of entry, a fact reflected as a gut-directed HR profile in
patients with a natural typhoid infection. These data complement
the view that in contrast to Vi, vaccination with Ty21a closely
imitates the natural typhoid infection.
Serum antibodies are the classical approach to studying
humoral immune responses. While serum antibodies provide
information on the systemic immune response, the plasmablast
assays (ELISPOT and ALS) describe the total response elicited in
the body. Consistent with previous studies [13,16,33], the
ELISPOT assay assessing the response at single-cell level proved
to be the most sensitive approach to the evaluation of the response.
Consistent with the level of protection reported in field trials, the
magnitude of the typhoid-specific plasmablast responses to Vi and
Ty21a vaccines are similar. However, there is a difference in the
expected localization of the response, and the antigenic specificity.
Only the response to Ty21a vaccination was found to imitate
closely that in a natural infection. Surprisingly, the antigen
specificity assays also revealed a significant O-antigen-specific
response in the Vi group, presumably caused by trace amounts of
lipopolysaccharide remaining in the vaccine preparation after
purification. It remains possible that part of the immunity
conferred by the Vi vaccine may, in fact, be contributed by a
response to typhoidal O-antigens.
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Table 4. Antibody responses in serum and ALS cultures.
Assay Vi vaccine Ty21a vaccine
IgA IgG IgM IgA/IgG/IgM IgA IgG IgM IgA/IgG/IgM
Serum antibody ELISA Vi: n = 25
Ty21a: n = 25
4 4 4 8 (32%) 7 5 12 13 (52%)
ALS ELISA Vi: n = 11 Ty21a: n = 12 1 0 1 1 (9%) 11 4 10 11 (84%)
ELISPOT Vi: n = 25 Ty21a: n = 25 22 19 22 24 (96%) 24 18 24 25 (100%)
Numbers of vaccinees responding in serum, ALS culture and ELISPOT assays for Salmonella Typhi in the Vi and Ty21a groups. In the ELISA assays (serum and ALS), a
responder was defined as an individual with at least two-fold increase in titre (in IgA, IgG and/or IgM isotype). In the ELISPOT assay, a responder was defined as having at
least 3 ASC/106 PBMC on day 7. Blood samples for ELISPOT and ALS analyses were collected on days 0 and 7, and serum samples on days 0 and 28 after vaccination. The
number of vaccinees tested with each assay is indicated in the left row.
doi:10.1371/journal.pone.0060583.t004
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